APrevent
APrevent is a medical device company developing the VOIS adjustable vocal implant for treating unilateral vocal fold paralysis and the AiSpeak AI-powered speech conversion platform for dysarthria patients, selling to hospitals, ENT surgeons, and healthcare providers globally.
- Company typePrivate
- Founded2013
- HeadquartersTaipei, Taiwan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What APrevent does
APrevent is a medical device company founded in 2013 that develops surgical implants and AI-assisted speech software for patients with voice and communication disorders. Its flagship product, APrevent® VOIS (Vocal Implant System), is an adjustable long-term implant made of biocompatible medical-grade silicone and titanium used in medialization thyroplasty to treat unilateral vocal fold paralysis (UVFP) and glottic insufficiency. VOIS's distinguishing technical feature is an integrated port that allows surgeons to inject saline solution both intraoperatively and postoperatively in an office-based setting, enabling fine-tuning of glottic closure without revision surgery. The standardized instrument set reduces operative time from approximately 2 hours to 30-40 minutes. The company's second product, AiSpeak, is a SaaS speech conversion platform that uses AI machine learning and speech recognition to assist dysarthria patients with daily communication, with integrations on Qualcomm C610 and Snapdragon 888 processors using the Snapdragon Neural Processing Engine for edge inference.
APrevent generates revenue primarily through hardware sales of the VOIS Vocal Implant System to hospitals and ENT surgeons, supplemented by subscription/recurring revenue potential from the AiSpeak SaaS platform. The company employs a B2B enterprise go-to-market combining direct field sales (e.g., 43 German hospitals with NUB reimbursement), channel partners (Endotherapeutics for Australia), and surgeon education through hands-on training workshops at leading medical institutions. APrevent holds CE Mark (2020), TFDA approval (June 2023), TGA approval (Australia), and ISO 13485:2016 certification for its Austrian manufacturing subsidiary. The company is headquartered in Taipei, Taiwan with its ISO 13485-certified manufacturing and operations based in Vienna, Austria (APrevent Biotech GmbH), and has raised approximately $10 million in disclosed venture funding across Series C ($4M, 2018) and Series D ($6M, March 2024 led by Taiwania Capital).
APrevent firmographics
Firmographics- Name
- APrevent
- Legal name
- APrevent Biotech GmbH
- Website
- https://apreventmed.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- APrevent is a medical device company developing the VOIS adjustable vocal implant for treating unilateral vocal fold paralysis and the AiSpeak AI-powered speech conversion platform for dysarthria patients, selling to hospitals, ENT surgeons, and healthcare providers globally.
- Ownership category
- akta.pro rank
APrevent industry classification
Industry- Product category
- Laryngeal Implants / ENT Medical Devices
- NAICS
- Telephone Apparatus Manufacturing (334210), Other Sound Recording Industries (512290), Sound Recording Industries (5122)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Contact Center Speech AI (agent assist, IVR automation) (HDAAAFAL)
- akta.pro secondary industry
- Speech Enhancement & Noise Suppression (AEC/NR) (HDAAAFAG)
Keywords
Where APrevent is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices3 records
Markets served
APrevent business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- VOIS Vocal Implant System Sales: APrevent generates revenue through the sale of its VOIS Vocal Implant System - an adjustable long-term medical implant for treating glottic insufficiency. The product is sold to hospitals and ENT surgeons for implantation procedures.
- AiSpeak SaaS Platform: APrevent offers AiSpeak, a Software-as-a-Service speech conversion platform for speech disorder (dysarthria) patients, providing recurring subscription revenue from patients and healthcare providers.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
APrevent product offering
Product offeringCore offering
APrevent develops, manufactures, and sells the APrevent® VOIS Vocal Implant System, an adjustable long-term laryngeal implant made of medical-grade silicone and titanium used in medialization thyroplasty to treat glottic insufficiency caused by unilateral vocal fold paralysis; the implant is unique in offering both intra-operative and post-operative saline-injection adjustment via an integrated port. The company also offers AiSpeak, a Software-as-a-Service speech conversion platform that uses AI machine learning and speech recognition to assist patients with dysarthria (slurred speech) in daily communication, with edge-AI integration on Qualcomm Snapdragon processors.
Product overview
APrevent offers two core products: APrevent® VOIS (VOCAL IMPLANT SYSTEM), an innovative adjustable long-term implant for medialization thyroplasty treatment of unilateral vocal fold paralysis and glottic insufficiency; and AiSpeak, a cloud-based speech conversion SaaS platform that uses AI/ML to assist dysarthria patients with speech recognition and communication. VOIS is a hardware medical device made of silicone and titanium with unique intra/postoperative adjustability, while AiSpeak is a software platform leveraging 5G and AI technologies. The company operates ISO 13485 certified subsidiaries in Austria (APrevent Biotech GmbH) and Taiwan (APrevent Medical Ltd.).
Differentiator
Problem solved
Functional benefit
Brands
- APrevent VOIS: VOCAL IMPLANT SYSTEM - An adjustable long-term implant to treat glottic insufficiency, featuring unique intra- and post-operative adjustability using medical-grade silicone and titanium materials
- AiSpeak
Products and services
- APrevent® VOIS Vocal Implant System An adjustable long-term laryngeal implant made of medical-grade silicone and titanium, used in medialization thyroplasty to treat unilateral vocal fold paralysis and glottic insufficiency. The first implant offering both intra-operative and post-operative adjustment via saline injection through an integrated port. Sold to hospitals and ENT surgeons for surgical implantation.
- AiSpeak A Software-as-a-Service (SaaS) AI-powered speech conversion platform that uses machine learning and speech recognition to assist patients with dysarthria (slurred speech) in daily communication. Integrates with Qualcomm Snapdragon C610 and Snapdragon 888 processors via the Snapdragon Neural Processing Engine for on-device inference.
Quantifiable outcome
- 72.73% of patients required postoperative saline adjustments that further enhanced voice outcomes
- +4 more outcomes
Companies that use APrevent
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
APrevent technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature5 records
APrevent partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Linkou Chang-Gung Memorial HospitalcoreHost institution for 2024 Phonosurgery and Neurolaryngology Course featuring APrevent VOIS Type 1 Thyroplasty Hands-on Workshop with human cadavers. Supported by Ministry of Economic Affairs Project Office of A+ Industrial Innovative R&D Program.
- Endotherapeutics Pty. Ltd.corePartnership to develop Australia market for VOIS implant. Endotherapeutics is a leading Australian medical technologies company with over 20 years experience. APrevent VOIS has received TGA approval for the Australian market.
- Medical University of Vienna - Center of Anatomy and Cell BiologycoreHost institution for APrevent VOIS Type 1 Thyroplasty Hands-on Workshop providing surgical training to physicians on VOIS implantation procedures.
- German Healthcare Systemcore43 German hospitals have approved APrevent VOIS for German NUB (New examination and treatment methods subsidy) at Status 1 level, up from 4 hospitals in 2021. The NUB is a payment scheme for innovative medical technologies in Germany with only 20% approval rate.
- Universiti Kebangsaan Malaysia Medical Centre (UKMMC)minorHost institution for 18th Malaysia Laryngeal and Phonosurgery Workshop 2024, providing hands-on training on VOIS implantation for regional ENT surgeons.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
APrevent competitors and assessment
Company assessmentDirect peers
- InHealth Technologies: InHealth manufactures the Montgomery Thyroplasty Implant System, the established gold-standard medialization implant for unilateral vocal fold paralysis — directly competing with APrevent VOIS in the same surgical indication and surgeon base.
- Atos Medical: Atos Medical (acquired by Coloplast in 2021) is a global leader in voice prostheses and laryngectomy care, including the Provox system. It serves the same ENT/laryngology clinician base treating glottic insufficiency and voice restoration, with overlapping reimbursement and training infrastructure.
- Boston Medical Products: Boston Medical Products (a Colson Medical affiliate) manufactures thyroplasty and laryngeal implants (including Montgomery system distribution). Direct competitor to APrevent in medialization thyroplasty for UVFP.
- Heinz Kurz GmbH: Heinz Kurz is a German-based ENT implant manufacturer producing titanium medialization systems and other laryngeal implants — directly competitive with VOIS in the DACH market where APrevent has built its strongest NUB presence.
- Spiggle & Theis Medizintechnik: Spiggle & Theis is a German manufacturer of ENT surgical devices, including vocal fold medialization implants. Operates in the same DACH ENT surgical market as APrevent with overlapping hospital customers.
- Voiceitt: Voiceitt is an Israel-based AI speech recognition company specifically targeting dysarthria and speech-impairment use cases — directly competitive with APrevent's AiSpeak platform on the same end-user population and technology stack.
Emerging players
- SpeechVive: SpeechVive produces a wearable speech-cueing device for individuals with Parkinson's disease and similar dysarthria conditions. Overlaps with APrevent's AiSpeak target population but addresses speech-impairment via a hardware rather than AI-software approach.
Broad incumbents
- Cochlear Limited: Cochlear is the global leader in cochlear implants with embedded speech processing and AI-driven sound mapping. Comparable to APrevent in combining an implantable medical device with proprietary speech AI processing, though serving hearing-impairment rather than voice-production indications.
- MED-EL: MED-EL is a major cochlear implant manufacturer with advanced speech coding strategies and AI-enhanced signal processing — analogous to APrevent in pairing implantable hardware with proprietary speech-processing technology, though in the hearing-impairment space.
- Coloplast: Coloplast acquired Atos Medical in 2021 to build its voice and laryngectomy franchise and is now APrevent's largest competitor in the broader voice/ENT implantable device space, with deeper capital, reimbursement, and surgeon relationships globally.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
APrevent social profiles
Digital presenceAPrevent compliance and trust
Trust signalCompliance4 records
APrevent financial estimates
Financial estimateRevenue estimate
Valuation estimate
APrevent leadership team
Management profileNumber of profiles
Profiles3 records
APrevent subsidiaries and ownership
Company hierarchySubsidiaries2 records
APrevent funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
APrevent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about APrevent
What does APrevent do?
APrevent develops, manufactures, and sells the APrevent® VOIS Vocal Implant System, an adjustable long-term laryngeal implant made of medical-grade silicone and titanium used in medialization thyroplasty to treat glottic insufficiency caused by unilateral vocal fold paralysis; the implant is unique in offering both intra-operative and post-operative saline-injection adjustment via an integrated port. The company also offers AiSpeak, a Software-as-a-Service speech conversion platform that uses AI machine learning and speech recognition to assist patients with dysarthria (slurred speech) in daily communication, with edge-AI integration on Qualcomm Snapdragon processors.
Is APrevent a public or private company?
APrevent is a private company. It is classified as venture growth investor backed and is currently operating.
When was APrevent founded?
APrevent was founded in 2013. It employs 11 to 50 people.
Where is APrevent based?
APrevent is headquartered in Taipei, Taiwan, in the Asia region.
How does APrevent make money?
Two revenue lines are on record. VOIS Vocal Implant System Sales are the primary driver. The others are aiSpeak SaaS Platform.
Who are APrevent's main competitors?
Direct peers on record are InHealth Technologies, Atos Medical, Boston Medical Products, Heinz Kurz GmbH, Spiggle & Theis Medizintechnik and Voiceitt. SpeechVive is listed as an emerging player. Broad incumbents are Cochlear Limited, MED-EL and Coloplast.
Does APrevent have an API?
No public API is recorded for APrevent.
What industry is APrevent in?
APrevent's product category is Laryngeal Implants / ENT Medical Devices. Its primary akta.pro industry code is HDAAAFAL, Contact Center Speech AI (agent assist, IVR automation), with a secondary code of HDAAAFAG, Speech Enhancement & Noise Suppression (AEC/NR). Its NAICS code is 334210 and its SIC code is 3841.